Arkeos Therapeutics is a clinical-stage oncology company developing targeted radiopharmaceuticals that use alpha-emitting radioisotopes to treat cancer patients across multiple tumor types. The company has built a proprietary miniprotein radioconjugate platform designed to deliver tumor-killing radiation with high selectivity and prolonged retention while minimizing systemic exposure, offering pharmacokinetic advantages over larger antibodies and faster clearance than traditional peptides. Arkeos generates value through product sales from approved radiopharmaceuticals, milestone payments and royalties from collaborations (notably a partnership with Eli Lilly), and addresses a large market opportunity by targeting diverse solid tumors where existing marketed radiopharmaceutical platforms have limited application; the company also builds integrated manufacturing and supply chain capabilities to overcome historical bottlenecks in radiopharmaceutical production and isotope access.